Research sheds light on what causes severe inflammatory bowel disease.

Published Date: 26 Apr 2023

Researchers from Cedars-Sinai have discovered a genetic variation that raises the risk of perianal Crohn's disease, the most crippling form of the condition, in susceptible individuals.

Read Full News

Latest News

ANTHEM-UC: Icotrokinra Shows Sustained Efficacy in Moderate-to-Severe Ulcerative Colitis, With Vipul Jairath, MBChB, DPhil Vipul Jaraith, MBChB, DPhil

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Joshua Wechsler, MD, on dupilumab's sustained efficacy in pediatric patients with EoE Joshua Wechsler, MD, MSCI

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

NASPGHAN: Best Practices for Celiac Disease Follow-up with Dale Lee, MD Dale Lee, MD

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Julie Khlevner, MD, AGAF, Reacts to the FDA Approval of Linaclotide for Pediatric IBS-C Julie Khlevner, MD, AGAF

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Rimegepant Linked to Increased Rectal Compliance, Reduced Rectal Sensation in IBS, With Ayah Matar, MD Ayah Matar, MD

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

Todays Updates

NLX-112 Shows Safety and Tolerability in Phase 2a Parkinson Trial, Supporting Further Development Louie Pasculli

A phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.

AskBio’s Late-Onset Pompe Disease Gene Therapy AB-1009 Cleared for Phase 1/2 Trial Noah Stansfield

AskBio noted that AB-1009 also recently received fast track and orphan drug designations from the FDA.

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

Todays Updates

NLX-112 Shows Safety and Tolerability in Phase 2a Parkinson Trial, Supporting Further Development Louie Pasculli

A phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.

AskBio’s Late-Onset Pompe Disease Gene Therapy AB-1009 Cleared for Phase 1/2 Trial Noah Stansfield

AskBio noted that AB-1009 also recently received fast track and orphan drug designations from the FDA.

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

Latest News

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

News All Time

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

H. pylori Geographical Prevalence and NASPGHAN/ESPGHAN Guidelines, With Silvana Bonilla, MD Silvana Bonilla, MD

Multicenter data presented by Silvana Bonilla, MD, at NASPGHAN 2025 highlight regional variation in pediatric H. pylori prevalence and support selective biopsy practices guided by clinical suspicion.

5 Gastroenterology Headlines You Missed in November 2025

5 Gastroenterology Headlines You Missed in November 2025

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

HCPLive 5 Stories in Under 5: Week of 10/05 Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

FDA Approves Updated Indication for Upadacitinib (Rinvoq) in IBD Abigail Brooks, MA

The decision updates the indication statements for ulcerative colitis and Crohn’s disease to allow use in patients who have received ≥ 1 approved systemic therapy.

Empirical Donor Selection, 2-Dose Capsule FMT Regimen Improve C Diff Cure Rates Abigail Brooks, MA

Findings from the quality improvement study provide real-world data supporting empirical donor exclusion and multiple-dose capsule FMT to increase CDI cure rates.

Conference Preview: American College of Gastroenterology’s 2025 Annual Scientific Meeting Abigail Brooks, MA

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

ACP Releases Position Paper on Colorectal Cancer Screening, Surveillance Abigail Brooks, MA

The ACP Performance Measurement Committee reviewed 5 performance measures for CRC screening, ultimately only supporting 1 of them.

Recommended News For You

a brand-new generic therapy for different types of cancer.

A pilot study investigates a novel strategy for lowering anxiety and enhancing post-stem cell transplant quality of life.

Biomarker panel offers hope for early pancreatic cancer detection

Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most

Increased anti-tumor response and reduced side effects from immune checkpoint inhibitors.

In breast cancer patients with nodes positive, preoperative hydroxyprogesterone may enhance disease-free survival.

Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma

Recommended Articles For You

AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency 

Polyposis Syndrome: Causes, Symptoms, and Treatment Options 

Tertiary Lymphoid Structures: Pivotal Players in Cancer Prognosis and Therapeutic Response 

Elevating Hematology Oncology: Modern Approaches for Smarter Diagnosis and Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Healthcare in the Mix in President Biden's Farewell Address

2.

A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.

3.

Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation

4.

Many Americans unaware of links between HPV and cancers, poll reveals

5.

Ineffective medication can remove the "worst fear" of schizophrenia.

1.

Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization

2.

Managing High Potassium Levels: A Comprehensive Guide to Veltassa 

3.

Can Wearables and AI Become a Gamechanger for Histiocytic Cancer Detection?

4.

Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment

5.

Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion

2.

Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC

3.

Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care

4.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

5.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot